StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38−0.07 (-4.83%)

Close on Nov 17, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Inhibikase Therapeutics's enterprise value was $56.19M on Nov 11, 2026, against $36.39M a year earlier. Over the last 5 years it ranged from -$17.88M to $145.98M, with a median of $260.41K.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$56.19M-26.1%
2025Dec 31, 2025$76.03M+259.3%
2024Dec 31, 2024$21.16M–
2023Dec 29, 2023-$9.87M–
2022Dec 30, 2022-$13.78M–
2021Dec 31, 2021-$9.64M–

More Inhibikase Therapeutics figures

See a number that looks wrong?